Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Amodiaquine (Test)
Amodiaquine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Amodiaquine (Pfizer) | EXPERIMENTAL | - |
| Amodiaquine tablets (Arsuamoon-Guilin China) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Amodiaquine (Test) | DRUG | Oral tablet, single dose, 1 X 300 MG |
| Amodiaquine (Comparator) | DRUG | Oral tablet, single dose, 2 X 150 MG |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive. * BMI of 18 to 30 kg/m2; and a total body weight \>45 kg (99 lbs). * An informed consent document signed and dated by the subject or a legally acceptable representative. Exclusion Criteria: *...
Amodiaquine is being studied for the treatment of Falciparum Malaria, an infectious disease caused by the Plasmodium falciparum parasite. It is a small molecule therapeutic candidate. The clinical program is focused on this specific malaria indication.
Amodiaquine is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer is the sponsor of the clinical program for this asset.
Amodiaquine is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program includes one completed trial.
Amodiaquine has been evaluated in one completed Phase 1 trial, NCT00894660, titled a bioequivalence study comparing Amodiaquine tablet (Pfizer) to Amodiaquine tablets (Arsuamoon-Guilin China) in healthy subjects. The trial enrolled 38 participants in Singapore and was active-controlled.
Yes, Amodiaquine is also known as Amodiaquine (Test). Both names refer to the same investigational drug candidate being developed by Pfizer for Falciparum Malaria.